Recent progress in the treatment of cardiovascular disease using olmesartan

References

• Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001;104:365–72
   PubMed Web of Science ®Google Scholar
• Imaizumi S, Miura S, Yahiro E, et al. Class- and molecule-specific differential effects of angiotensin II type 1 receptor blockers. Curr Pharm Des 2013;19:3002–8
   PubMed Web of Science ®Google Scholar
• Miura S, Fujino M, Hanzawa H, et al. Molecular mechanism underlying inverse agonist of angiotensin II type 1 receptor. J Biol Chem 2006;281:19288–95
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557–65
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tuzcu EM, Schoenhagen P, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005;352:29–38
   PubMed Web of Science ®Google Scholar
• Ambrose JA, Winters SL, Arora RR, et al. Angiographic evolution of coronary artery morphology in unstable angina. J Am Coll Cardiol 1986;7:472–8
   PubMed Web of Science ®Google Scholar
• Ambrose JA, Tannenbaum MA, Alexopoulos D, et al. Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol 1988;12:56–62
   PubMed Web of Science ®Google Scholar
• Little WC, Constantinescu M, Applegate RJ, et al. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation 1988;78:1157–66
   PubMed Web of Science ®Google Scholar
• Giroud D, Li JM, Urban P, et al. Relation of the site of acute myocardial infarction to the most severe coronary arterial stenosis at prior angiography. Am J Cardiol 1992;69:729–32
   PubMed Web of Science ®Google Scholar
• Nobuyoshi M, Kimura T, Ohishi H, et al. Restenosis after percutaneous transluminal coronary angioplasty: pathologic observations in 20 patients. J Am Coll Cardiol 1991;17:433–9
   PubMed Web of Science ®Google Scholar
• Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903–13
   PubMed Web of Science ®Google Scholar
• Ogihara T, Kikuchi K, Matsuoka H, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 2009;32:3–107
   PubMed Web of Science ®Google Scholar
• Klingbeil AU, Schneider M, Martus P, et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003;115:41–6
   PubMed Web of Science ®Google Scholar
• Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861–9
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362:759–66
   PubMed Web of Science ®Google Scholar
• Miura S, Imaizumi S, Saku K. Recent progress in molecular mechanisms of angiotensin II type 1 and 2 receptors. Curr Pharm Des 2013;19:2981–7
   PubMed Web of Science ®Google Scholar
• Miura S, Fujino M, Hanzawa H, et al. Molecular mechanism underlying inverse agonist of angiotensin II type 1 receptor. J Biol Chem 2006;281:19288–95
   PubMed Web of Science ®Google Scholar
• Miura S, Kiya Y, Kanazawa T, et al. Differential bonding interactions of inverse agonists of angiotensin II type 1 receptor in stabilizing the inactive state. Mol Endocrinol 2008;22:139–46
   PubMed Web of Science ®Google Scholar
• Yasuda N, Miura S, Akazawa H, et al. Conformational switch of angiotensin II type 1 receptor underlying mechanical stress-induced activation. EMBO Rep 2008;9:179–86
   PubMed Web of Science ®Google Scholar
• Fujino M, Miura S, Kiya Y, et al. A small difference in the molecular structure of AT1 receptor blockers induces AT1 receptor-dependent and -independent beneficial effects. Hypertens Res 2010;33:1044–52
   PubMed Web of Science ®Google Scholar
• Miura S, Okabe A, Matsuo Y, et al. Unique binding behavior of the recently approved angiotensin II receptor blocker azilsartan compared to that of candesartan. Hypertens Res 2013;36:134–9
   PubMed Web of Science ®Google Scholar
• Kiya Y, Miura S, Fujino M, et al. Clinical and pharmacotherapeutic relevance of the double-chain domain of the angiotensin II type 1 receptor blocker olmesartan. Clin Exp Hypertens 2010;32:129–36
   PubMed Web of Science ®Google Scholar
• Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Renin--angiotensin system and cardiovascular risk. Lancet 2007;369:1208–19
   PubMed Web of Science ®Google Scholar
• Fliser D, Buchholz K, Haller H; European Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EUTOPIA) Investigators. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004;110:1103–7
   PubMed Web of Science ®Google Scholar
• Rolph MS, Zimmer S, Bottazzi B, et al. Production of the long pentraxin PTX3 in advanced atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2002;22:e10–14
   PubMed Web of Science ®Google Scholar
• Inoue K, Sugiyama A, Reid PC, et al. Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris. Arterioscler Thromb Vasc Biol 2007;27:161–7
   PubMed Web of Science ®Google Scholar
• Iwata A, Miura S, Tanaka T, et al. Plasma pentraxin-3 levels are associated with coronary plaque vulnerability and are decreased by statin. Coron Artery Dis 2012;23:315–21
   PubMed Web of Science ®Google Scholar
• Norata GD, Marchesi P, Pulakazhi Venu VK, et al. Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis. Circulation 2009;120:699–708
   PubMed Web of Science ®Google Scholar
• Miura S. Stop the inflammation. Prog Med 2012;32:2631–6 (in Japanese)
   Google Scholar
• Takai S, Jin D, Sakaguchi M, et al. The regressive effect of an angiotensin II receptor blocker on formed fatty streaks in monkeys fed a high-cholesterol diet. J Hypertens 2005;23:1879–86
   PubMed Web of Science ®Google Scholar
• Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007;370:937–48
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004;291:1071–80
   PubMed Web of Science ®Google Scholar
• Nissen SE, Nicholls SJ, Wolski K, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008;299:1561–73
   PubMed Web of Science ®Google Scholar
• Hirohata A, Yamamoto K, Miyoshi T, et al. Impact of olmesartan on progression of coronary atherosclerosis a serial volumetric intravascular ultrasound analysis from the OLIVUS (impact of OLmesarten on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) trial. J Am Coll Cardiol 2010;55:976–82
   PubMed Web of Science ®Google Scholar
• Hirohata A, Yamamoto K, Miyoshi T, et al. Four-year clinical outcomes of the OLIVUS-Ex (impact of Olmesartan on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) extension trial. Atherosclerosis 2012;220:134–8
   PubMed Web of Science ®Google Scholar
• Sugihara M, Miura S, Takamiya Y, et al. Safety and efficacy of anti-hypertensive therapy with add-on angiotensin II type 1 receptor blocker after successful coronary stent implantation. Hypertens Res 2009;32:625–30
   PubMed Web of Science ®Google Scholar
• Ishii H, Kobayashi M, Kurebayashi N, et al. Impact of angiotensin II receptor blocker therapy (olmesartan or valsartan) on coronary atherosclerotic plaque volume measured by intravascular ultrasound in patients with stable angina pectoris. Am J Cardiol 2013;112:363--8
   PubMed Web of Science ®Google Scholar